NCS
—
For a probably critical medical situation, it’s outstanding how few individuals know they’ve obstructive sleep apnea (OSA).
OSA, through which an individual’s higher airway collapses, inflicting irregular respiratory, is the most common sleep-related respiratory situation. One examine estimated nicely over 900 million adults between 30 and 69 years outdated could have it worldwide, although as many as four in five moderate-to-severe cases are undiagnosed. Left untreated, it can improve the danger of hypertension, heart problems, fireplace assault, stroke, and sort 2 diabetes, and but untreated is what most instances — identified and undiagnosed — are.
The excellent news is that for individuals with a analysis, there have by no means been extra methods to treatment the issue. With the worldwide sleep apnea gadget market valued at $8.52 billion in 2024 and projected to rise to practically $13 billion by 2030, according to one 2025 report, medical tech firms are growing new options.
Continuous optimistic airway strain (CPAP) machines, which push air into the mouth to preserve open airways, are extremely efficient and have lengthy been thought-about the gold customary therapy.
However, CPAP can have a excessive preliminary dropout fee, with customers citing the discomfort of carrying a masks strapped to the face, or the approach to life variations required to use the machine.
Despite CPAP’s dominance, {the marketplace} for options is opening up. Mandibular advancement devices worn over tooth maintain the decrease jaw and tongue ahead; neurostimulation implants set off the hypoglossal nerve into motion to stop the tongue and mushy tissues from blocking airways; there’s additionally a drug being trialed that’s designed to stimulate the nerve.
Another different is unfavourable strain gadgets, which in contrast to CPAP, suck as a substitute of blow, pulling the tongue and mushy tissues up and ahead within the mouth. So far, such gadgets haven’t been proven to be as efficient as CPAP, however the know-how is slowly discovering its place out there, with Taiwanese firm Somnics Health carving out a foothold.
Roughly the dimensions of a smartphone, Somnics’ iNAP is a battery-powered gadget that attaches to a slender tube with a versatile mouthpiece on the different finish. That is worn contained in the mouth, and as soon as switched on, unfavourable strain retains airways open. Users then breathe via their nostril as regular.
“The beauty of it is it allows natural breathing … and it’s a very comfortable, quiet and efficient solution,” stated Somnics basic supervisor Olivier Lauzeral in a video interview.
The iNAP was conceived over a decade in the past by Somnics founder Chung Chu Chen, who mixed his analysis with mental property bought from US firm Apnicure (which went out of enterprise in 2017, stated Lauzeral) to create a unfavourable strain product. Initial R&D and scientific work passed off in Taiwan, the place it was first accepted by authorities. Since then it has been regularly launched to new markets throughout Asia and Europe, profitable multiple design awards.
In 2020 it was cleared by the US Food and Drug Administration to be used within the United States amongst adults with obstructive sleep apnea who received’t use CPAP. Today, round 3,000 sufferers use the iNAP within the US, stated Lauzeral, and round 10,000 worldwide.
While research have proven that unfavourable strain gadgets are much less efficient than CPAP, Lauzeral stated that the corporate’s goal market is sufferers who determine not to use CPAP and mandibular gadgets, however aren’t prepared for a surgical resolution like neurostimulation.
“Seventy percent of our patients are ‘CPAP failing,’” he defined. “That was our first way to adopt patients — to talk to those who had that experience with CPAP. The other 30% are what we call ‘naïve patients,’ (meaning) they hadn’t tried any other treatments before.”
Lauzeral hopes that the comfort of a discreet and transportable gadget that may run for 5 nights on a single cost will appeal to sufferers from youthful demographics.
“Half of the population with sleep apnea is younger than 53,” he stated. “Loads of these sufferers don’t need to contact a CPAP.
“What’s sad to see is those people being in denial, not wanting to be treated when they’re in their 30s or early 40s. They don’t get into their treatment, then their sleep apnea deteriorates… 10 years later they have no choice but getting into CPAP and at that point their health is really not good.”
Somnics has not too long ago launched a subscription mannequin within the US, whereby sufferers pays for the gadget in installments over 24 months, which retails at $1,399.
Unlike most CPAP machines, the prescription-only iNAP is just not at the moment lined by medical insurance within the US, although Lauzeral stated Somnics is hoping to change this.
Dr. Hrayr Attarian, a sleep medication specialist and professor of neurology at Northwestern University Feinberg School of Medicine, informed NCS that there want to be greater research on the efficacy of iNAP.
“The research out there was done in small groups of people,” he stated in an e mail. “Even with those limitations,” research confirmed enhancements in 75% and 83% of sufferers, “vs. close to 95% with CPAP,” he added.
Attarian characterised the gadget as “an alternative but not a replacement for CPAP,” although agreed that Somnics’ therapy was “less intrusive.”
Surveying the market, though “OSA treatments are going to be more fragmented… nothing so far has the same efficacy of CPAP,” he stated. To grow to be a viable competitor, unfavourable strain producers want to conduct scientific trials with “a larger number of participants with all degrees of (OSA) severity,” he added.
Dr. Johan Verbraecken, pulmonologist and medical coordinator on the Sleep Disorders Centre, Antwerp University Hospital, agreed that extra analysis would assist set up the effectiveness of the iNAP. Currently, it’s not a first-line therapy, he stated — significantly for extreme instances of OSA. Verbraecken described it as an “add-on treatment instead of a standalone treatment.”
He stated that the iNAP has minimal unwanted effects however argued that to compete with CPAP, the product wants to extra successfully scale back sufferers’ Apnea-Hypopnea Index (AHI) — how typically an individual’s respiratory slows or stops throughout sleep.
“There has always been an interest in (CPAP) alternatives,” he stated. “These numbers grow, given more patients get the diagnosis, while the absolute number of people not tolerant to CPAP is growing accordingly. On the other hand, the dropout rate is lowering, given better CPAP and mask technology.”
Somnics might be banking that there’ll proceed to be a proportion of sufferers who will stay averse to CPAP. “We’re ready to start working with partners that will help us really get to the next level and grow and capture all those patients,” stated Lauzeral.